Press Resease

Macrolide Drugs Market by Drug Type (14-membered ring agents, 14-membered ring agents, 15-membered ring agents (Azalides), 16-membered ring agents, and Ketolides), By Distribution Channels (Hospital pharmacies, Clinics, Hospitals, Retail pharmacies, and Online pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2024

Published Date: 13-Jul-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3230 Status : Published

Global macrolide drugs market expected to generate revenue of around USD 7.66 billion by end of 2024, growing at a CAGR of around 3.2% between 2018 and 2024. Macrolides are a class of antibacterial drugs that contain large macrocyclic lactone ring. One or more deoxy-sugars, usually desosamine and cladinose are attached to the macrocyclic lactone ring.

Description

The report covers forecast and analysis for the macrolide drugs market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the macrolide drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the macrolide drugs market on a global level.

In order to give the users of this report a comprehensive view of the macrolide drugs market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein types, sales channel, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis. 

Global Macrolide Drugs Market

The study provides a decisive view of the macrolide drugs market by segmenting the market based on types, sales channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on type, macrolide drugs market has been segmented into 14-membered ring agents, 14-membered ring agents, 15-membered ring agents (Azalides), 16-membered ring agents, and Ketolides. Based on the sales channel, the macrolide drugs market has been segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies. Based on region, macrolide drugs market is further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for macrolide drugs market based on individual segment and sales channel in all the regions and countries.

The report also includes detailed profiles of end players such as Abbott Laboratories, Akorn, Inc., Eli Lilly & Co., Fresenius Kabi USA, Gland Pharma Limited, Neo Química, Macrolide Pharmaceuticals, Mylan N.V., Pfizer, Inc., Sanofi, Merck & Co., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and WOCKHARDT. 

This report segments the global macrolide drugs market as follows:

Global Macrolide Drugs Market: By Type

  • 14-membered ring agents 
  • 15-membered ring agents (Azalides)
  • 16-membered ring agents
  • Ketolides

Global Macrolide Drugs Market: By Sales Channel     

  • Hospital pharmacies
  • Clinics
  • Hospitals
  • Retail pharmacies
  • Online pharmacies

Global Macrolide Drugs market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Macrolide Drugs market, 2015 - 2024 (USD Billion)
    • 2.2. Global Macrolide Drugs market : Snapshot
  •  
  • Chapter 3. Macrolide Drugs market- Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Macrolide Drugs market drivers: Impact analysis
      • 3.2.2. Increasing incidences of cancer
      • 3.2.3. Increasing geriatric population
    • 3.3. Market Restraints
      • 3.3.1. Global Macrolide Drugs market restraints: Impact analysis
      • 3.3.2. Lack of infrastructure
    • 3.4. Opportunities
      • 3.4.1. Technological advancements in Macrolide Drugs market Types
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type segment
      • 3.6.2. Market attractiveness analysis, by sales channel segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Macrolide Drugs market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Macrolide Drugs market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Type Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Macrolide Drugs market - Type Segment Analysis
    • 5.1. Global Macrolide Drugs market: Type overview
      • 5.1.1. Global Macrolide Drugs market revenue share, by Type, 2015 and 2024
    • 5.2. 14-membered ring agents
      • 5.2.1. Global 14-membered ring agents market, 2015 - 2024(USD Billion)
    • 5.3. 15-membered ring agents (Azalides)
      • 5.3.1. Global 15-membered ring agents (Azalides) market, 2015 - 2024(USD Billion)
    • 5.4. 16-membered ring agents
      • 5.4.1. Global 16-membered ring agents market, 2015 - 2024(USD Billion)
    • 5.5. Ketolides
      • 5.5.1. Global Ketolides market, 2015 - 2024(USD Billion)
  •  
  • Chapter 6. Global Macrolide Drugs market -Sales Channel Segment Analysis
    • 6.1. Global Macrolide Drugs market: Sales Channel overview
      • 6.1.1. Global Macrolide Drugs market revenue share, by sales channel, 2015 and 2022
    • 6.2. Hospital pharmacies
      • 6.2.1. Global Hospital pharmacies market, 2015 - 2024(USD Billion)
    • 6.3. Clinics
      • 6.3.1. Global Clinics market, 2015 - 2024(USD Billion)
    • 6.4. Hospitals
      • 6.4.1. Global Hospitals market, 2015 - 2024(USD Billion)
    • 6.5. Retail pharmacies
      • 6.5.1. Global Retail pharmacies market, 2015 - 2024(USD Billion)
    • 6.6. Online pharmacies
      • 6.6.1. Global Online pharmacies market, 2015 - 2024(USD Billion)
  •  
  • Chapter 7. Global Macrolide Drugs market - Regional Segment Analysis
    • 7.1. Global Macrolide Drugs market: Regional overview
      • 7.1.1. Global Macrolide Drugs market revenue share, by region, 2015 and 2021
    • 7.2. North America
      • 7.2.1. North America Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
      • 7.2.2. North America Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.2.3.2. U.S. Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.2.4. Canada
        • 7.2.4.1. Canada Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.2.4.2. Canada Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.2.5.2. Rest of North America Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
      • 7.3.2. Europe Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.3. Germany
        • 7.3.3.1. Germany Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.3.2. Germany Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.4. U.K.
        • 7.3.4.1. U.K. Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.4.2. U.K. Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.5. France
        • 7.3.5.1. France Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.5.2. France Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.6. Italy
        • 7.3.6.1. Italy Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.6.2. Italy Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.7. Spain
        • 7.3.7.1. Spain Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.7.2. Spain Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.8. Russia
        • 7.3.8.1. Russia Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.8.2. Russia Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.3.9. Rest of Europe
        • 7.3.9.1. Rest of Europe Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.3.9.2. Rest of Europe Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
      • 7.4.2. Asia Pacific Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.4.3.2. China Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.4.4.2. Japan Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.4.5.2. India Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.4.6. Australia
        • 7.4.6.1. Australia Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.4.6.2. Australia Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
      • 7.5.2. Latin America Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.5.3. Mexico
        • 7.5.3.1. Mexico Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.5.3.2. Mexico Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.5.4. Brazil
        • 7.5.4.1. Brazil Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.5.4.2. Brazil Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.5.5. Argentina
        • 7.5.5.1. Argentina Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.5.5.2. Argentina Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.5.6. Rest of Latin America
        • 7.5.6.1. Rest of Latin America Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.5.6.2. Rest of Latin America Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Macrolide Drugs market revenue, by Type, 2015 - 2024(USD Billion)
      • 7.6.2. Middle East and Africa Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.6.3. Saudi Arabia
        • 7.6.3.1. Saudi Arabia Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.6.3.2. Saudi Arabia Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.6.4. UAE
        • 7.6.4.1. UAE Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.6.4.2. UAE Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.6.5. Qatar
        • 7.6.5.1. Qatar Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.6.5.2. Qatar Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.6.6. South Africa
        • 7.6.6.1. South Africa Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.6.6.2. South Africa Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
      • 7.6.7. Rest of Middle East & Africa
        • 7.6.7.1. Middle East & Africa Macrolide Drugs market revenue, by type, 2015 - 2024(USD Billion)
        • 7.6.7.2. Middle East & Africa Macrolide Drugs market revenue, by sales channel, 2015 - 2024(USD Billion)
  •  
  • Chapter 8. Company Profile
    • 8.1. Abbott Laboratories
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Akorn, Inc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Eli Lilly & Co.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Fresenius Kabi USA
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Gland Pharma Limited
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Macrolide Pharmaceuticals
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Neo Química
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Mylan N.V.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Pfizer, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Merck & Co.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
    • 8.11. Merck & Co.
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Therapy portfolio
      • 8.11.4. Business strategy
      • 8.11.5. Recent developments
    • 8.12. Sandoz International GmbH
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Therapy portfolio
      • 8.12.4. Business strategy
      • 8.12.5. Recent developments
    • 8.13. Teva Pharmaceutical Industries Ltd.
      • 8.13.1. Overview
      • 8.13.2. Financials
      • 8.13.3. Therapy portfolio
      • 8.13.4. Business strategy
      • 8.13.5. Recent developments
    • 8.14. WOCKHARDT
      • 8.14.1. Overview
      • 8.14.2. Financials
      • 8.14.3. Therapy portfolio
      • 8.14.4. Business strategy
      • 8.14.5. Recent developments

Methodology

Free Analysis

Macrolides are a class of antibacterial drugs that contain large macrocyclic lactone ring. One or more deoxy-sugars, usually desosamine and cladinose are attached to the macrocyclic lactone ring. The macrocyclic lactone ring generally is 14, 15, or 16 membered. Macrolides antibiotic is derived from Saccharopolyspora erythracea. Macrolides inhibit the protein synthesis in bacteria. The inhibition of protein synthesis is carried out by binding to the 50s ribosome. Macrolides are more effective against the gram-positive bacteria as well as the intracellular pathogens like Chlamydia, Mycoplasma, and Legionella. Macrolides primarily act as bacteriostatic agents opposite to several strains of Moxicella, Staphylococci Streptococci, Corynebacteria, Clostridia, Listeria, Neisseria meningitides, and Haemophilus sp.

Primary bacterial resistance to macrolides occurs due to the post-translational methylation of 23s bacterial rRNA. Because of mutation, the bacterial resistance is either plasmid-mediated or chromosomal. This results in the cross-resistance of macrolides, streptogramins, and lincosamides. Other two rarely seen acquired resistances are the production of drug-inactivating enzymes, as well as the production of active ATP-dependent efflux proteins which transport the drug outside of the cell.

Macrolide drugs market is expected to have a moderate growth during the forecast period attributing to the increasing prevalence of infectious diseases, in turn increasing the demand for drugs against the infections. Furthermore, a rising elderly population, an alarming rate of increasing number of multi-strain resistant bacterial strains as well as better benefits over the conventional antibiotics are driving factors for the macrolide drugs market. Macrolide drug is good for oral absorption; it is easy for absorption in tissues and also has an easier dosage of once or twice a day. Macrolide drug has very low incidences of side-effects. A study stated that macrolide may increase the risk of a sudden cardiac arrest, ventricular tachyarrhythmias, and cardiovascular deaths, also GI disturbances and inhibition of hepatic metabolism may hinder the growth of macrolide drugs market.

Global Macrolide Drugs Market

Based on the type, macrolide drugs market has been segmented into 14-membered ring agents, 14-membered ring agents, 15-membered ring agents (Azalides), 16-membered ring agents, and Ketolides. Based on distribution channel, macrolide drugs market has been segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies. Based on region, macrolide drugs market is further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America is anticipated to remain the principal region over the forecast period. Rising healthcare understanding and awareness about the drugs against the infections is expected to boost the market in this region. Europe was the second largest market followed by Asia Pacific. Asia Pacific is probably expected to show the highest growth rate during the forecast period while Latin America market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa region is also expected to show a noticeable growth in the years to come with increasing awareness.

Some of the key players in macrolide drugs market include Abbott Laboratories, Akorn, Inc., Eli Lilly & Co., Fresenius Kabi USA, Gland Pharma Limited, Neo Química, Macrolide Pharmaceuticals, Mylan N.V., Pfizer, Inc., Sanofi, Merck & Co., Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and WOCKHARDT, among others.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social